Stewardship

In this global economy, nearly every competitor has access to big breakthroughs in technology and to the equipment and capital to produce standardized products, but those regions that possess the human capital, with its insights, competencies, and experience will have the competitive advantage.

Pete Pellerito discusses what is being done to provide the workforce for this broad and growing industry.

Society has tapped just a small fraction of the many potential uses and benefits of biotechnology.

Mankind's need to cure disease, combat hunger and discover new forms of energy has never been more urgent.

Moree discusses the Forum and the importance of partnering to improving the health of people in developing countries.

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year's BIO International Convention.

Learn more about the history of biotechnology.

The U.S. bioscience industry continued to score employment gains through 2008 - the first year of the recent economic downturn, according to a study released today by Battelle and the Biotechnology Industry Organization (BIO).

Plant-made pharmaceuticals (PMPs) and plant-made industrial products (PMIPs) offer an innovative way to turn biotech plants into "factories" that can produce therapeutic proteins, enzymes, and other industrial compounds and proteins.

The agricultural biotechnology industry is committed to the safe and responsible use of its technology.

Today, field testing remains a vital tool to understand the value and performance of new biotech products.

Growers using biotechnology understand that strict adherence to regulations and the best industry practices are key not only to maintaining the use of current technology, but also to gaining the use of future traits.

Commercial seed production has evolved significantly since Gregor Mendel first bred a few peas in an Austrian monastery.

January 24 2013
To ensure transparency and communication between patients and their treatment teams, BIO believes that certain safeguards should guide substitution policies for interchangeable biologics under state law as well.
October 4 2010
BIO policy recommends that BIO members anticipate, consider and develop approaches to help manage and mitigate any potential significant, unintentional processing, product functional or compositional negative effects in crop use or processing streams.
Comments are regarding conservation and stewardship requirements, matching payments, establishment costs and annual payments, disclosure of competitively sensitive information, invasiveness determination and review, consistency with existing FSA programs, corporations and publicly traded company participation, eligible materials, and algae.
June 6 2012
The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."
March 2 2012
The Biotechnology Industry Organization (BIO) announced today that it has integrated its alliance development activities into one department as a means of expanding engagement opportunities with external groups that share a commitment to unleashing biotechnology’s capability to benefit patients and consumers.
February 9 2012
BIO President and CEO Jim Greenwood issued the following statement regarding the newly released U.S. Food and Drug Administration (FDA) guidance for the review and approval of biosimilars.
October 13 2011
BIO President and CEO Jim Greenwood released the following statement on the Obama Administration's intent to create a National Bioeconomy Blueprint.
October 7 2011
In a case brought against USDA’s Animal and Plant Health Inspection Service (APHIS), the U.S. District Court for the Southern District of Florida has denied the plaintiff’s motion for summary judgment and granted the summary judgment motions for the government, ArborGen, and BIO.